Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Taiho Decitabine and Cedazuridine Research Grant Opportunity: Submit by Tuesday, January 19, 2021
Study Proposal Submission-NCCN iEnvision
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

NCCN and Pfizer, Inc. Grant Opportunity

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer’s Independent Grants for Learning & Change (IGLC) team to offer a grant opportunity focused on  improving care for patients with rare types of cancers such as renal cell carcinoma and certain hematologic malignancies, where treatment options are complex and rapidly advancing. The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of Letters of Intent (LOIs). 

The intent of this RFP is to encourage organizations to submit LOIs describing concepts and ideas for design and implementation of systems or programs that close clinical practice gaps and improve the care of patients with rare cancer types through the establishment of education and support mechanisms for community oncologists.

NCCN views this collaboration with Pfizer’s IGLC team as clear recognition of the advantages offered to industry through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.

LOIs are due by 11:59 PM EST, Thursday, December 5, 2013. If you have any questions regarding this RFP, please direct them in writing to the Grant Officer for this clinical area, Jacqueline Waldrop at Jacqueline.waldrop@pfizer.com with the subject line, “Oncology Communities RFP.”

View RFP for the NCCN/Pfizer, Inc. Grant Opportunity

View Pfizer, Inc. Grant Application System